---
title: "Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286945953.md"
description: "Analyst Anthony Vendetti from Maxim Group has reaffirmed a Buy rating on PAVmed, maintaining a price target of $16. He cites the company's expanding oncology platforms, strategic partnerships, and the rollout of the Veris Cancer Care Platform as key factors. Vendetti highlights PAVmed's stake in Lucid Diagnostics and the momentum of EsoGuard testing, along with the relaunch of its medical device portfolio, as supporting elements for his rating."
datetime: "2026-05-19T15:45:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286945953.md)
  - [en](https://longbridge.com/en/news/286945953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286945953.md)
---

# Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16

PAVmed, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Anthony Vendetti from Maxim Group reiterated a Buy rating on the stock and has a $16.00 price target.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Anthony Vendetti has given his Buy rating due to a combination of factors tied to PAVmed’s expanding oncology-focused platforms and strategic partnerships. He highlights the ongoing rollout of the Veris Cancer Care Platform, including the commercial phase at The Ohio State University Comprehensive Cancer Center, where the program aims to enroll up to 1,000 patients by the end of 2026, supporting long-term adoption.

Vendetti also points to PAVmed’s 15% stake in Lucid Diagnostics and the continued momentum of EsoGuard testing, with anticipated Medicare coverage and a growing footprint in VA facilities expected to drive incremental revenue. In addition, he notes the relaunch of PAVmed’s medical device portfolio, the resumption of implantable monitor development ahead of an expected FDA submission, and what he views as adequate capital to fund these initiatives, all of which underpin his unchanged $16 price target and reaffirmed Buy rating.

Vendetti covers the Healthcare sector, focusing on stocks such as Lucid Diagnostics, Icecure Medical, and Daxor. According to TipRanks, Vendetti has an average return of \-22.3% and a 23.59% success rate on recommended stocks.

### Related Stocks

- [PAVM.US](https://longbridge.com/en/quote/PAVM.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [LUCD.US](https://longbridge.com/en/quote/LUCD.US.md)
- [ICCM.US](https://longbridge.com/en/quote/ICCM.US.md)
- [DXR.US](https://longbridge.com/en/quote/DXR.US.md)
- [PAVMZ.US](https://longbridge.com/en/quote/PAVMZ.US.md)

## Related News & Research

- [PAVmed Reports Q1 2026 Results and Business Update](https://longbridge.com/en/news/286567652.md)
- [Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)](https://longbridge.com/en/news/286443716.md)
- [Do Wall Street Analysts Like Welltower Stock?](https://longbridge.com/en/news/286776714.md)
- [Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. | SOPH Stock News](https://longbridge.com/en/news/286227729.md)
- [How Chubb’s (CB) New Canada Cancer Coverage Launch Could Reframe Its Health Benefits Strategy](https://longbridge.com/en/news/286787301.md)